查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462973

脊椎生物製剂市场、占有率、规模、趋势、产业分析报告：依产品、最终用户、地区、细分市场、预测，2024-2032 年

Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，到 2032 年，全球脊椎生物製剂市场预计将达到 31.6 亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

脊椎生物製品市场是由全球医疗支出增加所推动的。 随着越来越多的资源被分配用于治疗退化性椎间盘疾病和椎骨骨折等脊椎疾病，对脊椎生物製剂等创新治疗的需求不断增加。 医疗保健支出的增加将促使脊椎应用的先进生物製剂的研究和开发增加投资，例如骨移植替代品和干细胞疗法。 此外，支出的增加将支持增强 MRI 和 CT 扫瞄等诊断技术的使用，从而促进早期检测和治疗。 采用微创手术技术与脊椎生物製剂结合，为患者提供了传统手术的微创替代方案，有助于降低成本，同时推动市场成长。

由于脊椎融合手术（通常用于治疗退化性椎间盘疾病和椎骨骨折）的应用不断扩大，脊椎生物製剂市场也在成长。 生物製剂促进骨骼生长并增加脊椎稳定性，使融合手术成功。 生物技术的进步促进了创新脊椎生物製剂的发展，为复杂的脊椎疾病提供了解决方案。 这些产品促进骨再生，改善患者的治疗效果并减少额外介入的需要。 随着人口老化和退化性脊椎疾病的日益流行，对脊椎生物製剂的需求不断增加。 外科医生正在将生物製剂纳入治疗方案，以满足患者对更好治疗结果的期望。 脊椎生物治疗应用的监管批准进一步推动了市场扩张并推动脊椎生物製剂市场的成长。

个人化医疗是一种根据遗传倾向、生活方式和疾病特征量身订做治疗的方法。 先进的基因测试和生物标记分析使临床医生能够为每位患者选择最合适的生物製剂，优化疗效并最大限度地减少副作用。 此外，个人化医疗促进了针对特定患者亚群定制的新型生物製剂的开发，例如基因治疗和精准靶向生物製剂。 医疗保健提供者、研究人员和生物技术公司之间的这种合作将促进脊椎生物製剂的创新，并提供更有效、以患者为中心的治疗。

由于经济的快速成长和医疗基础设施的改善，新兴市场正在为脊椎生物製品市场创造机会。 在亚太、拉丁美洲和中东等地区，随着老化和城市化导致脊椎疾病盛行率增加，对先进医疗保健的需求不断增加。 医疗保健支出的增加促进了对创新技术的投资，包括脊椎生物製品。 跨国公司和当地医疗保健提供者之间的合作促进了产品的引入和采用。 这些合作伙伴关係促进知识交流和市场开发，以满足新兴市场不断变化的医疗保健需求。

脊椎生物製品市场报告亮点

2023年，同种异体脊椎移植领域因其临床接受度高、疗效可靠且疾病传播风险极低而占了重要的销售占有率。

2023 年，由于全面的护理服务、先进的基础设施和经验丰富的医疗保健专业人员，医院和诊所部门占了很大的销售占有率。

2023年，由于先进的医疗基础设施、脊椎疾病的高盛行率以及完善的监管框架，北美地区占了主要市场占有率。

市场遍布全球，包括 Arthrex, Inc.、Johnson &Johnson、Medtronic plc、NuVasive, Inc.、Organogenesis Inc.、Orthofix Medical Inc.、Stryker Corporation 和 Zimmer Biomet Holdings, Inc.。的存在。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球脊椎生物製剂市场洞察

  • 脊椎生物製品市场 - 产业概况
  • 脊椎生物製剂市场动态
    • 推动者和机会
      • 由于脊椎疾病的发生率不断增加，对该产品的需求预计会增加。
      • 人们对微创手术的兴趣日益浓厚，预计将推动脊椎生物製品市场的成长
    • 抑制因素和课题
      • 治疗成本上升可能阻碍市场成长
  • 杵分析
  • 脊椎生物製品产业的趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第 5 章依产品划分的世界市场

  • 主要发现
  • 简介
  • 骨移植替代物
  • 同种异体脊椎移植物
  • 其他

第 6 章最终使用者的世界市场

  • 主要发现
  • 简介
  • 医院和诊所
  • 门诊手术中心
  • 其他

第 7 章依地区划分的世界市场

  • 主要发现
  • 简介
    • 脊椎生物製品市场评估，地区，2019-2032
  • 脊椎生物製剂市场 - 北美
    • 北美：脊椎生物製剂市场，依最终用户划分，2019-2032 年
    • 北美：脊椎生物製品市场（依产品），2019-2032 年
    • 脊椎生物製品市场 - 美国
    • 脊椎生物製品市场 - 加拿大
  • 脊椎生物製剂市场 - 欧洲
    • 欧洲：脊椎生物製剂市场，依最终使用者划分，2019-2032 年
    • 欧洲：脊椎生物製剂市场（依产品），2019-2032 年
    • 脊椎生物製品市场 - 英国
    • 脊椎生物製品市场 - 法国
    • 脊椎生物製品市场 - 德国
    • 脊椎生物製品市场 - 义大利
    • 脊椎生物製剂市场 - 西班牙
    • 脊椎生物製品市场 - 荷兰
    • 脊椎生物製剂市场 - 俄罗斯
  • 脊椎生物製剂市场 - 亚太地区
    • 亚太地区：脊椎生物製剂市场，依最终使用者划分，2019-2032 年
    • 亚太地区：脊椎生物製剂市场（依产品），2019-2032 年
    • 脊椎生物製品市场 - 中国
    • 脊椎生物製剂市场 - 印度
    • 脊椎生物製品市场 - 马来西亚
    • 脊椎生物製品市场 - 日本
    • 脊椎生物製剂市场 - 印尼
    • 脊椎生物製剂市场 - 韩国
  • 脊椎生物製剂市场 - 中东和非洲
    • 中东和非洲：脊椎生物製品市场，依最终用户划分，2019-2032 年
    • 中东和非洲：脊椎生物製剂市场（依产品），2019-2032 年
    • 脊椎生物製品市场 - 沙乌地阿拉伯
    • 脊椎生物製品市场 - 阿联酋
    • 脊椎生物製品市场 - 以色列
    • 脊椎生物製品市场 - 南非
  • 脊椎生物製剂市场 - 拉丁美洲
    • 拉丁美洲：脊椎生物製剂市场，依最终用户划分，2019-2032 年
    • 拉丁美洲：脊椎生物製品市场，依产品，2019-2032 年
    • 脊椎生物製品市场 - 墨西哥
    • 脊椎生物製品市场 - 巴西
    • 脊椎生物製品市场 - 阿根廷

第八章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 合作/协作/合约/出版物

第九章公司简介

  • Arthrex, Inc
  • Baxter International Inc.
  • Exactech, Inc.
  • Globus Medical Inc.
  • Johnson & Johnson（DePuy Synthes）
  • Kuros Biosciences
  • Medtronic plc
  • NuVasive, Inc.
  • Organogenesis Inc.
  • Orthofix Medical Inc.
  • RTI Surgical Holdings, Inc.
  • SeaSpine Holdings Corporation
  • Spine Wave, Inc.
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
Product Code: PM4665

The global spine biologics market size is expected to reach USD 3.16 billion by 2032, according to a new study by Polaris Market Research. The report "Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The spine biologics market is driven by increasing global healthcare expenditure. With more resources allocated to treating spinal disorders like degenerative disc disease and spinal fractures, demand for innovative treatments such as spine biologics is rising. Higher healthcare spending enables greater investment in research, leading to advanced biologic products tailored for spinal applications like bone graft substitutes and stem cell therapies. Additionally, increased expenditure supports enhanced access to diagnostic technologies like MRI and CT scans, facilitating early detection and treatment. Adoption of minimally invasive surgical techniques, coupled with spine biologics, offers patients less invasive alternatives to traditional surgeries, driving market growth while contributing to cost savings.

The spine biologics market is also growing due to expanding applications in spine fusion procedures, commonly performed for degenerative disc disease and spinal fractures. Biologic products promote bone growth and enhance spinal stability, facilitating successful fusion. Advancements in biotechnology have led to innovative spine biologics, offering solutions for complex spinal conditions. These products stimulate bone regeneration, improving patient outcomes and reducing the need for additional interventions. With an aging population and increasing prevalence of degenerative spine conditions, demand for spine biologics is rising. Surgeons are integrating biologic products into treatment protocols to meet patient expectations for better outcomes. Regulatory approvals for biologic treatments in spinal applications further support market expansion, driving growth in the spine biologics market.

Personalized medicine approaches tailor treatments based on genetic makeup, lifestyle, and disease characteristics. Advanced genetic testing and biomarker analysis enable clinicians to select the most suitable biologic therapies for each patient, optimizing efficacy and minimizing side effects. Additionally, personalized medicine fosters the development of novel biologic treatments, including gene therapies and precision-targeted biologics, customized to specific patient subgroups. This collaborative effort between healthcare providers, researchers, and biotech firms drives innovation in spine biologics, offering more effective and patient-centric treatments.

Emerging markets are fostering opportunities in the spine biologics market owing to rapid economic growth and healthcare infrastructure development. In regions like Asia-Pacific, Latin America, and the Middle East, rising demand for advanced medical treatments accompanies the increasing prevalence of spinal disorders due to aging populations and urbanization. Heightened healthcare expenditure enables investment in innovative technologies, including spine biologics. Collaborations between multinational corporations and local healthcare providers facilitate product introduction and adoption. These partnerships drive knowledge exchange and localized development to meet the evolving healthcare needs of emerging markets.

Spine Biologics Market Report Highlights

In 2023, the spinal allografts segment held a significant revenue share owing to clinical acceptance, proven efficacy, and minimal disease transmission risk.

In 2023, the hospitals and clinics segment held a significant revenue share owing to comprehensive care services, advanced infrastructure, and experienced healthcare professionals.

In 2023, the North America region accounted for a significant market share due to advanced healthcare infrastructure, high prevalence of spinal disorders, and well-established regulatory framework.

The market is highly competitive owing to the existence of market players with a global presence, including Arthrex, Inc., Johnson & Johnson, Medtronic plc, NuVasive, Inc., Organogenesis Inc., Orthofix Medical Inc., Stryker Corporation, and Zimmer Biomet Holdings, Inc. among others.

Polaris Market Research has segmented the Spine Biologics market report based on product, end user, and region:

Spine Biologics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Bone Graft Substitutes
  • Spinal Allografts
  • Others

Spine Biologics, End User Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

Spine Biologics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Spine Biologics Market Insights

  • 4.1. Spine Biologics Market - Industry Snapshot
  • 4.2. Spine Biologics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of spinal disorders is projected to spur the product demand
      • 4.2.1.2. Growing preference for minimally invasive procedures is expected to drive spine biologics market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Spine Biologics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Spine Biologics Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Spine Biologics, by Product, 2019-2032 (USD Billion)
  • 5.3. Bone Graft Substitutes
    • 5.3.1. Global Spine Biologics Market, by Bone Graft Substitutes, by Region, 2019-2032 (USD Billion)
  • 5.4. Spinal Allografts
    • 5.4.1. Global Spine Biologics Market, by Spinal Allografts, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Spine Biologics Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 6.3. Hospitals and Clinics
    • 6.3.1. Global Spine Biologics Market, by Hospitals and Clinics, by Region, 2019-2032 (USD Billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Spine Biologics Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Spine Biologics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Spine Biologics Market - North America
    • 7.3.1. North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.3.2. North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.3. Spine Biologics Market - U.S.
      • 7.3.3.1. U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.4. Spine Biologics Market - Canada
      • 7.3.4.1. Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4. Spine Biologics Market - Europe
    • 7.4.1. Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.3. Spine Biologics Market - UK
      • 7.4.3.1. UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.4. Spine Biologics Market - France
      • 7.4.4.1. France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.5. Spine Biologics Market - Germany
      • 7.4.5.1. Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.6. Spine Biologics Market - Italy
      • 7.4.6.1. Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.7. Spine Biologics Market - Spain
      • 7.4.7.1. Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.8. Spine Biologics Market - Netherlands
      • 7.4.8.1. Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.9. Spine Biologics Market - Russia
      • 7.4.9.1. Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5. Spine Biologics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.3. Spine Biologics Market - China
      • 7.5.3.1. China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.4. Spine Biologics Market - India
      • 7.5.4.1. India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.5. Spine Biologics Market - Malaysia
      • 7.5.5.1. Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.6. Spine Biologics Market - Japan
      • 7.5.6.1. Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.7. Spine Biologics Market - Indonesia
      • 7.5.7.1. Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.8. Spine Biologics Market - South Korea
      • 7.5.8.1. South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6. Spine Biologics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.3. Spine Biologics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.4. Spine Biologics Market - UAE
      • 7.6.4.1. UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.5. Spine Biologics Market - Israel
      • 7.6.5.1. Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.6. Spine Biologics Market - South Africa
      • 7.6.6.1. South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.7. Spine Biologics Market - Latin America
    • 7.7.1. Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.3. Spine Biologics Market - Mexico
      • 7.7.3.1. Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.4. Spine Biologics Market - Brazil
      • 7.7.4.1. Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.5. Spine Biologics Market - Argentina
      • 7.7.5.1. Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Arthrex, Inc
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Baxter International Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Exactech, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Globus Medical Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Johnson & Johnson (DePuy Synthes)
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Kuros Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Medtronic plc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. NuVasive, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Organogenesis Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Orthofix Medical Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. RTI Surgical Holdings, Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. SeaSpine Holdings Corporation
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Spine Wave, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Stryker Corporation
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Zimmer Biomet Holdings, Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables

  • Table 1 Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 2 Global Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 3 Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 5 North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 6 U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 7 U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 8 Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 9 Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 10 Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 11 Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 12 UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 13 UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 14 France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 15 France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 16 Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 17 Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 18 Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 19 Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 20 Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 21 Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 24 Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 25 Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 28 China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 29 China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 30 India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 31 India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 34 Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 35 Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 38 South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 39 South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 44 UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 45 UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 46 Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 47 Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 48 South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 49 South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 51 Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 52 Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 53 Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 54 Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 55 Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 56 Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 57 Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Spine Biologics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End User
  • Figure 7 Global Spine Biologics Market, by End User, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Product
  • Figure 9 Global Spine Biologics Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 10 Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Spine Biologics Market